Rasagiline (Azilect, Azipron) is an irreversible inhibitor of monoamine oxidase-B[3] used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.[4]
The racemic form of the drug was invented by Aspro Nicholas in the early 1970s. Moussa B.H. Youdim identified it as a potential drug for Parkinson's disease, and working with collaborators at Technion – Israel Institute of Technology in Israel and the drug company, Teva Pharmaceuticals, identified the R-isomer as the active form of the drug.[5] Teva brought it to market in partnership with Lundbeck in Europe and Eisai in the US and elsewhere. It was approved in Europe in 2005 and in the US in 2006.
Rasagiline is used to treat symptoms of Parkinson's disease both alone and in combination with other drugs. It has shown efficacy in both early and advanced Parkinsons, and appears to be especially useful in dealing with non-motor symptoms like fatigue.[6][7][8]
Rasagiline has not been tested in pregnant women and is Pregnancy Category C in the US.[8]
^Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (June 2002). "An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells". Neuroscience Letters. 326 (2): 105–8. doi:10.1016/s0304-3940(02)00332-4. PMID 12057839. S2CID 29736753.
^Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^Oldfield V, Keating GM, Perry CM (2007). "Rasagiline: a review of its use in the management of Parkinson's disease". Drugs. 67 (12): 1725–47. doi:10.2165/00003495-200767120-00006. PMID 17683172. S2CID 195688993.
^Gallagher DA, Schrag A (2008). "Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease". CNS Drugs. 22 (7): 563–86. doi:10.2165/00023210-200822070-00003. PMID 18547126. S2CID 29707067.
^Lakhan SE (July 2007). "From a Parkinson's disease expert: Rasagiline and the future of therapy" (PDF). Molecular Neurodegeneration. 2 (1): 13. doi:10.1186/1750-1326-2-13. PMC 1929084. PMID 17617893.
^Stocchi F, Fossati C, Torti M (2015). "Rasagiline for the treatment of Parkinson's disease: an update". Expert Opinion on Pharmacotherapy. 16 (14): 2231–41. doi:10.1517/14656566.2015.1086748. PMID 26364897. S2CID 6823552.
^Poewe W, Mahlknecht P, Krismer F (September 2015). "Therapeutic advances in multiple system atrophy and progressive supranuclear palsy". Movement Disorders. 30 (11): 1528–38. doi:10.1002/mds.26334. PMID 26227071. S2CID 30312372.
^ abAzilect Prescribing Information Label last revised May, 2014
Rasagiline (Azilect, Azipron) is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease...
combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule. In addition to its neuroprotective properties...
conjugated by glucuronyltransferase. A newer anti-Parkinson MAO-B inhibitor, rasagiline, metabolizes into 1(R)-aminoindan, which has no amphetamine-like characteristics...
treatment, e.g. in multiple sclerosis Livedo reticularis associated with rasagiline Methylphenidate and dextroamphetamine-induced peripheral vasculopathy...
neurotoxicity led to development of alternative MAOB inhibitors, such as rasagiline, that do not produce toxic metabolites. When the nasal decongestant is...
in the causation and progression of macular degeneration and melanoma. Rasagiline, an important monotherapy drug in Parkinson's disease, has melanin binding...
agents like moclobemide, and MAOB selective agents such as selegiline, rasagiline, and pargyline, as well as the harmala alkaloids like harmine, harmaline...
14 days. MAO inhibitors include isocarboxazid, linezolid, phenelzine, rasagiline, selegiline, and tranylcypromine. Drinking alcohol can increase side effects...
of MAO-B, or inhibition of MAO-B through MAO-B inhibitors (Selegline, Rasagiline), slows the progression, improves and reverses the symptoms, associated...
Global Information
(what is this?) (verify)